Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Hofstetter, Christoph P ^a   Burkhardt, Jan Karl ^a   Shin, Benjamin J ^a   Gürsel, Demirkan B ^a   Mubita, Lynn ^a   Gorrepati, Ramana ^a   Brennan, Cameron ^b   Holland, Eric C ^b   Boockvar, John A ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN P53; CYCLIN G2; PHOSPHOPROTEIN PHOSPHATASE 2;

ADULT; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; BRAIN TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROTEIN SUBUNIT;

ADENOSINE TRIPHOSPHATE; BRAIN NEOPLASMS; CELL DEATH; CELL HYPOXIA; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN G2; FEMALE; G1 PHASE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASTIC STEM CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PHOSPHATASE 2; PROTEIN SUBUNITS; S PHASE;

EID: 84855644497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030059     Document Type: Article

References (60)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109.
3. The (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
4. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, et al. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313: 144-147.
5. Westermark B, Heldin CH, Nister M, (1995) Platelet-derived growth factor in human glioma. Glia 15: 257-263.
6. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang WT, et al. (2004) Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 10: 8177-8184.
7. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T, et al. (1996) Expression of tissue factor in glioma. Noshuyo Byori 13: 115-118.
8. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, et al. (2004) Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 64: 920-927.
9. Amberger-Murphy V, (2009) Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 9: 381-390.
10. Zhang TT, Platholi J, Heerdt PM, Hemmings HC Jr, Tung HY, (2008) Protein phosphatase-2A is activated in pig brain following cardiac arrest and resuscitation. Metab Brain Dis 23: 95-104.
11. Yung HW, Tolkovsky AM, (2003) Erasure of kinase phosphorylation in astrocytes during oxygen-glucose deprivation is controlled by ATP levels and activation of phosphatases. J Neurochem 86: 1281-1288.
12. Heikkinen PT, Nummela M, Leivonen SK, Westermarck J, Hill CS, et al. (2009) Hypoxia-activated Smad3-specific dephosphorylation by PP2A. J Biol Chem 285: 3740-3749.
13. Cho US, Xu W, (2007) Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445: 53-57.
14. Janssens V, Goris J, (2001) Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417-439.
15. MacKintosh C, Cohen P, (1989) Identification of high levels of type 1 and type 2A protein phosphatases in higher plants. Biochem J 262: 335-339.
16. Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, et al. (1988) Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci U S A 85: 1768-1771.
17. Fujiki H, Suganuma M, (1993) Tumor promotion by inhibitors of protein phosphatases 1 and 2A: the okadaic acid class of compounds. Adv Cancer Res 61: 143-194.
18. Casillas AM, Amaral K, Chegini-Farahani S, Nel AE, (1993) Okadaic acid activates p42 mitogen-activated protein kinase (MAP kinase; ERK-2) in B-lymphocytes but inhibits rather than augments cellular proliferation: contrast with phorbol 12-myristate 13-acetate. Biochem J 290 (Pt 2): 545-550.
19. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, et al. (2009) PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res 69: 2870-2877.
20. Fishbein JD, Dobrowsky RT, Bielawska A, Garrett S, Hannun YA, (1993) Ceramide-mediated growth inhibition and CAPP are conserved in Saccharomyces cerevisiae. J Biol Chem 268: 9255-9261.
21. Bennin DA, Don AS, Brake T, McKenzie JL, Rosenbaum H, et al. (2002) Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B′ subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest. J Biol Chem 277: 27449-27467.
22. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, et al. (1997) Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem 272: 12650-12661.
23. Ragel BT, Couldwell WT, Gillespie DL, Jensen RL, (2007) Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis. Neurosurg Rev 30: 181-187; discussion 187.
24. Bando H, Toi M, Kitada K, Koike M, (2003) Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231. Biomed Pharmacother 57: 333-340.
25. Leonard MO, Cottell DC, Godson C, Brady HR, Taylor CT, (2003) The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia. J Biol Chem 278: 40296-40304.
26. Hofstetter CP, Mannaa RH, Mubita L, Anand VK, Kennedy JW, et al. (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29: E6.
27. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
28. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, et al. (2010) The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119: 487-494.
29. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. (2009) Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4: 568-580.
30. Gursel D, Shin BJ, Burkhardt J, Kesavabhotla K, Schlaff CD, et al. (2011) Glioblastoma Stem-Like Cells- Biology and Therapeutic Implications. Cancers 3: 2655-2666.
31. Gursel DB, Beyene RT, Hofstetter C, Greenfield JP, Souweidane MM, et al. (2011) Optimization of glioblastoma multiforme stem cell isolation, transfection, and transduction. J Neurooncol.
32. Christensen E, (1987) Multivariate survival analysis using Cox's regression model. Hepatology 7: 1346-1358.
33. Colella S, Ohgaki H, Ruediger R, Yang F, Nakamura M, et al. (2001) Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes. Int J Cancer 93: 798-804.
34. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, et al. (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62: 564-576; discussion 564-576.
35. Ivan M, Kondo K, Yang H, Kim W, Valiando J, et al. (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468.
36. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, et al. (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472.
37. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, et al. (2009) Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 106: 11697-11702.
38. Martiniova L, Lu J, Chiang J, Bernardo M, Lonser R, et al. (2011) Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy. PLoS One 6: e14678.
39. Korkolopoulou P, Patsouris E, Konstantinidou AE, Pavlopoulos PM, Kavantzas N, et al. (2004) Hypoxia-inducible factor 1alpha/vascular endothelial growth factor axis in astrocytomas. Associations with microvessel morphometry, proliferation and prognosis. Neuropathol Appl Neurobiol 30: 267-278.
40. Heller IH, Elliott KA, (1955) The metabolism of normal brain and human gliomas in relation to cell type and density. Can J Biochem Physiol 33: 395-403.
41. Mahaley MS Jr, (1966) The in vitro respiration of normal brain and brain tumors. Cancer Res 26: 195-197.
42. Warburg O, (1926) Über den Stoffwechsel von Tumoren Berlin Springer.
43. Hossmann KA, Mies G, Paschen W, Szabo L, Dolan E, et al. (1986) Regional metabolism of experimental brain tumors. Acta Neuropathol 69: 139-147.
44. Mies G, Paschen W, Ebhardt G, Hossmann KA, (1990) Relationship between of blood flow, glucose metabolism, protein synthesis, glucose and ATP content in experimentally-induced glioma (RG1 2.2) of rat brain. J Neurooncol 9: 17-28.
45. Steinbach JP, Wolburg H, Klumpp A, Probst H, Weller M, (2003) Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death. Cell Death Differ 10: 823-832.
46. Favaro E, Nardo G, Persano L, Masiero M, Moserle L, et al. (2008) Hypoxia inducible factor-1alpha inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death. Am J Pathol 173: 1186-1201.
47. Chowdhury D, Keogh MC, Ishii H, Peterson CL, Buratowski S, et al. (2005) gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell 20: 801-809.
48. Goodarzi AA, Jonnalagadda JC, Douglas P, Young D, Ye R, et al. (2004) Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J 23: 4451-4461.
49. Li G, Elder RT, Qin K, Park HU, Liang D, et al. (2007) Phosphatase type 2A-dependent and-independent pathways for ATR phosphorylation of Chk1. J Biol Chem 282: 7287-7298.
50. Li HH, Cai X, Shouse GP, Piluso LG, Liu X, (2007) A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J 26: 402-411.
51. Yan Y, Cao PT, Greer PM, Nagengast ES, Kolb RH, et al. (2010) Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response. Oncogene 29: 4317-4329.
52. Jang YJ, Ji JH, Choi YC, Ryu CJ, Ko SY, (2007) Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A. J Biol Chem 282: 2473-2482.
53. Wykoff CC, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ, (2000) Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling. Oncogene 19: 6297-6305.
54. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ, (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90: 3322-3331.
55. Chen EY, Mazure NM, Cooper JA, Giaccia AJ, (2001) Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res 61: 2429-2433.
56. Kawano T, Fukunaga K, Takeuchi Y, Morioka M, Yano S, et al. (2001) Neuroprotective effect of sodium orthovanadate on delayed neuronal death after transient forebrain ischemia in gerbil hippocampus. J Cereb Blood Flow Metab 21: 1268-1280.
57. Junttila MR, Li SP, Westermarck J, (2008) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965.
58. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, et al. (2000) Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 288: 163-166.
59. Heikkinen PT, Nummela M, Jokilehto T, Grenman R, Kahari VM, et al. (2010) Hypoxic conversion of SMAD7 function from an inhibitor into a promoter of cell invasion. Cancer Res 70: 5984-5993.
60. Cohen P, Holmes CF, Tsukitani Y, (1990) Okadaic acid: a new probe for the study of cellular regulation. Trends Biochem Sci 15: 98-102.